Advertisement

Tumor Biology

, Volume 37, Issue 6, pp 7565–7572 | Cite as

Plasma DNA integrity index as a potential molecular diagnostic marker for breast cancer

  • Azza M. Kamel
  • Salwa Teama
  • Amal Fawzy
  • Mervat El Deftar
Original Article

Abstract

Plasma DNA integrity index is increased in various malignancies including breast cancer, the most common cancer in women worldwide; early detection is crucial for successful treatment. Current screening methods fail to detect many cases of breast cancer at an early stage. In this study, we evaluated the level of plasma DNA integrity index in 260 females (95 with breast cancer, 95 with benign breast lesions, and 70 healthy controls) to verify its potential value in discriminating malignant from benign breast lesions. The criteria of the American Joint Committee on Cancer were used for staging of breast cancer patients. DNA integrity index was measured by real-time PCR. DNA integrity index was significantly higher in breast cancer than in benign breast patients and healthy subjects (P = <0.001). DNA integrity index is correlated with TNM stage. Given 100 % specificity, the highest sensitivity achieved in detecting cancer group was 85.3 % at 0.55 DNA integrity index cutoff. In conclusion, the plasma DNA integrity index may be a promising molecular diagnostic marker of malignancy in breast lesions.

Keywords

Breast cancer DNA integrity index Real time PCR 

Notes

Compliance with ethical standards

Conflict of interest

None

Source of funding

None

Supplementary material

13277_2015_4624_Fig3_ESM.jpg (85 kb)
Fig. S1

Real Time PCR amplification for 400 bp β-actin gene of breast cancer patients: Each line presents one patient, the lower the CT, the higher the plasma DNA concentration (JPG 85 kb)

References

  1. 1.
    Abdulrahman Jnr GO, Rahman GA. Epidemiology of breast cancer in Europe and Africa. Review article. J Cancer Epidemiol. 2012;2012, 915610. doi: 10.1155/2012/915610.Google Scholar
  2. 2.
    Zaher ER, Anwar MM, Kohail HM, El-Zoghby SM, Abo-El-Eneen MS. Cell-free DNA concentration and integrity as a screening tool for cancer. Indian J Cancer. 2013;50:175–83. doi: 10.4103/0019-509X.118721.CrossRefPubMedGoogle Scholar
  3. 3.
    Omar S, Khaled H, Gaafar R, Zekry AR, Eissa S, El-Khatib O. Breast cancer in Egypt: a review of disease presentation and detection strategies. East Mediterr Health J = La Revue de Santé de la Méditerranée. 2003;9:448–63.Google Scholar
  4. 4.
    Mandel P, Metais P. Circulating nucleic acid. Acad Sci Paris. 1948;142:241–3.Google Scholar
  5. 5.
    Wang BG, Huang HY, Chen YC, Bristow RE, Kassauei K, Cheng CC, et al. Increased plasma DNA integrity in cancer patients. Cancer Res. 2003;63:3966–8.PubMedGoogle Scholar
  6. 6.
    Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in serum of cancer patients and the effect of therapy. Cancer Res. 1977;37:646–50.PubMedGoogle Scholar
  7. 7.
    Shapiro B, Chakrabarty M, Cohn EM, Leon SA. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer. 1983;51:2116–20.CrossRefPubMedGoogle Scholar
  8. 8.
    Anker P, Stroun M. Circulating DNA in plasma or serum. Medicina (B Aires). 2000;60(5 Pt 2):699–702.Google Scholar
  9. 9.
    Gormally E, Caboux E, Vineis P, Hainaut P. Circulating free DNA in plasma/serum as biomarker of carcinogenesis. Practical aspects and biological significance. Mutat Res. 2007;635:105–17.CrossRefPubMedGoogle Scholar
  10. 10.
    Elshimali YI, Khaddour H, Sarkissyan M, Wu Y, Vadgama JV. The clinical utilization of circulating cell free DNA in blood of cancer patients. Int J Mol Sci. 2013;14:18925–58. doi: 10.3390/ijms140918925.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Chan KC, Leung SF, Yeung SW, Chan AT, Lo YM. Aberrations in circulating DNA integrity after radiotherapy are associated with poor prognosis in nasopharyngeal carcinoma patients. Clin Cancer Res. 2008;14:4141–5. doi: 10.1158/1078-0432.CCR-08-0182.CrossRefPubMedGoogle Scholar
  12. 12.
    Giacona MB, Ruben GC, Iczkowski KA, Roos TB, Porter DM, Sorenson GD. Cell free DNA in human blood plasma, length measurements in patients with pancreatic cancer and healthy controls. Pancreas. 1998;17:89–97.CrossRefPubMedGoogle Scholar
  13. 13.
    Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor related protein. Nature. 1986;319(22):6–30.Google Scholar
  14. 14.
    Pupa SM, Ménard S, Morelli D, Pozzi B, De Palo G, Colnaghi MI. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene. 1983;8:2917–23.Google Scholar
  15. 15.
    Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, et al. The Her-2/neu gene and protein in breast cancer: biomarker and target of therapy. Oncologist. 2003;8:307–25.CrossRefPubMedGoogle Scholar
  16. 16.
    Anker P, Mulcahy H, Chen XQ, Stroun M. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev. 1999;18:65–73.CrossRefPubMedGoogle Scholar
  17. 17.
    Allen D, Butt A, Cahill D, Wheeler M, Popert R, Swaminathan R. Role of cell-free plasma DNA as a diagnostic marker for prostate cancer. Ann N Y Acad Sci. 2004;1022:76–80.CrossRefPubMedGoogle Scholar
  18. 18.
    Jung K, Stephan C, Lewandowski M, Klotzek S, Jung M, Kristiansen G, et al. Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer. Cancer Lett. 2004;205:173–80.CrossRefPubMedGoogle Scholar
  19. 19.
    Boddy JL, Gal S, Malone PR, Harris AL, Wainscoat JS. Prospective study of quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate disease. Clin Cancer Res. 2005;11:1394–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Ahlquist DA, Skoletsky JE, Boynton KA, Harrington JJ, Mahoney DW, Pierceall WE, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology. 2000;119:1219–27.CrossRefPubMedGoogle Scholar
  21. 21.
    Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev. 1994;3:67–71.PubMedGoogle Scholar
  22. 22.
    Vasioukhin V, Anker P, Maurice P, Lyautey J, Lederrey C, Stroun M. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol. 1994;86:774–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Jiajia Y, Guohao G, Shaoqing J. Recent advances in clinical applications of circulating cell-free DNA integrity. Lab Med. 2014;45:6–12.CrossRefGoogle Scholar
  24. 24.
    Boynton KA, Summerhayes IC, Ahlquist DA, Shuber AP. DNA integrity as a potential marker for stool-based detection of colorectal cancer. Clin Chem. 2003;49:1058–65.CrossRefPubMedGoogle Scholar
  25. 25.
    Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61:1659–65.PubMedGoogle Scholar
  26. 26.
    Chen XQ, Stroun M, Magnenat JL, Nicod LP, Kurt AM, Lyautey J, et al. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med. 1996;2:1033–5.CrossRefPubMedGoogle Scholar
  27. 27.
    Nawroz H, Koch W, Anker P, Stroun M, Sidransky D. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med. 1996;2:1035–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 1999;59:67–70.PubMedGoogle Scholar
  29. 29.
    Maebo A. Plasma DNA level as a tumor marker in primary lung cancer. Nihon Kyobu Shikkan Gakkai Zasshi. 1990;28:1085–91 (Abstract).PubMedGoogle Scholar
  30. 30.
    Umetani N, Giuliano AE, Hiramatsu SH, Amersi F, Nakagawa T, Martino S, et al. Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol. 2006;24:4270–6.CrossRefPubMedGoogle Scholar
  31. 31.
    Chang H-W, Lee SM, Goodman SN, Singer G, Cho S, Sokoll LJ, et al. Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J Natl Cancer Inst. 2002;94:1697–703.CrossRefPubMedGoogle Scholar
  32. 32.
    Agassi R, Czeiger D, Shaked G, Avriel A, Sheynin J, Lavrnkov K, et al. Measurement of circulating cell-free DNA levels by a simple fluorescent test in patients with breast cancer. Am J Clin Pathol. 2015;143(1):18–24. doi: 10.1309/AJCPI5YHG0OGFAHM.CrossRefPubMedGoogle Scholar
  33. 33.
    El-Shazly SF, Eid MA, El-Sourogy HA, Attia GF, Ezzat SA. Evaluation of serum DNA integrity as a screening and prognostic tool in patients with hepatitis C virus-related hepatocellular carcinoma. Int J Biol Markers. 2010;25:79–86.PubMedGoogle Scholar
  34. 34.
    Sunami E, Vu AT, Nguyen SL, Giuliano AE, Hoon DS. Quantification of LINE1 in circulating DNA as a molecular biomarker of breast cancer. Ann N Y Acad Sci. 2008;1137:171–4. doi: 10.1196/annals.1448.011.CrossRefPubMedGoogle Scholar
  35. 35.
    Gao YJ, He YJ, Yang ZL, Shao HY, Zuo Y, Bai Y, et al. Increased integrity of circulating cell free DNA in plasma of patients with acute leukemia. Clin Chem Lab Med. 2010;48:1651–6. doi: 10.1515/CCLM.2010.311.CrossRefPubMedGoogle Scholar
  36. 36.
    Kamel AM, Teama S, Fawzy A, El Deftar M. Increased plasma DNA integrity index in breast cancer patients. AACC. 2011; Abstract 09.Google Scholar
  37. 37.
    Sozzi G, Conte D, Mariani L, Lo Vullo S, Roz L, Lombardo C, et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res. 2001;61:4675–8.PubMedGoogle Scholar
  38. 38.
    Hanley R, Rieger-Christ KM, Canes D, Emara NR, Shuber AP, Boynton KA, et al. DNA integrity assay: a plasma-based screening tool for the detection of prostate cancer. Clin Cancer Res. 2006;12:4569–74.CrossRefPubMedGoogle Scholar
  39. 39.
    Mead R, Duku M, Bhandari P, Cree IA. Circulating tumour markers can define patients with normal colons, benign polyps, and cancers. Br J Cancer. 2011;105:239–24. doi: 10.1038/bjc.2011.230.CrossRefPubMedGoogle Scholar
  40. 40.
    Pinzani P, Salvianti F, Zaccara S, Massi D, De Giorgi V, Pazzagli M, et al. Circulating cell-free DNA in plasma of melanoma patients: qualitative and quantitative considerations. Clin Chim Acta. 2011;412:2141–5. doi: 10.1016/j.cca.2011.07.027.CrossRefPubMedGoogle Scholar
  41. 41.
    Casadio V, Calistri D, Tebaldi M, Bravaccini S, Gunelli R, Martorana G, et al. Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data. Urol Oncol. 2013;31(8):1744–50. doi: 10.1016/j.urolonc.2012.07.013.CrossRefPubMedGoogle Scholar
  42. 42.
    Sriram KB, Relan V, Clarke BE, Duhig EE, Windsor MN, Matar KS, et al. Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas. BMC Cancer. 2012;12:428. doi: 10.1186/1471-2407-12-428.CrossRefPubMedGoogle Scholar
  43. 43.
    Shi W, Lv C, Qi J, Zhao W, Wu X, Jing R, et al. Prognostic value of free DNA quantification in serum and cerebrospinal fluid in glioma patients. J Mol Neurosci. 2012;46:470–5. doi: 10.1007/s12031-011-9617-0.CrossRefPubMedGoogle Scholar
  44. 44.
    Madhavan D, Wallwiener M, Bents K, Zucknick M, Nees J, Schott S, et al. Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis. Breast Cancer Res Treat. 2014;146:163–73. doi: 10.1007/s10549-014-2946-2.CrossRefPubMedGoogle Scholar
  45. 45.
    Holdenrieder S, Burges A, Reich O, Spelsberg FW, Stieber P. DNA integrity in plasma and serum of patients with malignant and benign diseases. Ann N Y Acad Sci. 2008;1137:162–70. doi: 10.1196/annals.1448.013.CrossRefPubMedGoogle Scholar
  46. 46.
    Schmidt B, Weickmann S, Witt C, Fleischhacker M. Integrity of cell free plasma DNA in patients with lung cancer and nonmalignant lung disease. Ann N Y Acad Sci. 2008;1137:207–13. doi: 10.1196/annals.1448.034.CrossRefPubMedGoogle Scholar
  47. 47.
    Ellinger J, Bastian PJ, Haan KI, Heukamp LC, Buettner R, Fimmers R, et al. Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators. Int J Cancer. 2008;122:138–43.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of Clinical Pathology, National Cancer InstituteCairo UniversityCairoEgypt
  2. 2.Medical Research Center, Molecular Biology Unit, Faculty of MedicineAin Shams UniversityCairoEgypt
  3. 3.Department of Pathology, Tissue culture & Cytogenetic unit, National Cancer InstituteCairo UniversityCairoEgypt

Personalised recommendations